Last updated on October 14th, 2024 at 12:50 pm
Morbid obesity is a term that describes severe obesity, typically defined as having a body mass index (BMI) of 40 or higher.
-
- Must-Know Strategies for Managing Morbid Obesity and Improving Quality of Life
- How Does Mounjaro Work For Weight Loss & Obesity Treatment?
- Wegovy Versus Mounjaro: What Is the Best Option For Obesity Treatment?
- Morbid Obesity: Transform your life one step at a time
- Mounjaro and Wegovy for Weight Loss Reviews
- Source & Credits
It’s important to understand that morbid obesity isn’t just about carrying excess weight; it’s a severe medical condition that can significantly impact health and quality of life.
Health Risks of Morbid Obesity:
Morbid obesity is associated with numerous health risks, including:
- Heart Disease: Excess weight can strain the heart, leading to conditions like hypertension, coronary artery disease, and heart failure.
- Diabetes: Obesity is a significant risk factor for type 2 diabetes, as it can cause insulin resistance and impair glucose metabolism.
- Joint Problems: Carrying excess weight puts pressure on the joints, increasing the risk of osteoarthritis and joint pain.
- Sleep Apnea: Morbid obesity is a common cause of obstructive sleep apnea, a condition characterized by interrupted breathing during sleep.
- Mental Health Issues: Obesity can contribute to depression, anxiety, and low self-esteem due to societal stigma and physical limitations.
Healthy Eating Habits:
Adopting healthy eating habits is essential for managing morbid obesity.
Focus on:
- I eat a balanced diet of fruits, vegetables, lean proteins, and whole grains.
- It limits the intake of processed foods, sugary beverages, and high-fat snacks.
- I am practicing mindful eating by paying attention to hunger and fullness cues.
Managing morbid obesity requires a comprehensive approach that includes healthy eating habits, portion control, regular physical activity, and support from healthcare professionals.
Adopting these strategies and staying committed to your goals can improve your health, achieve sustainable weight loss, and enhance your overall quality of life.
Must-Know Strategies for Managing Morbid Obesity and Improving Quality of Life
The FDA has approved Lilly’s Mounjaro™ (tripeptide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes (Diabetes Treatment & Obesity Treatment). Diabetes is a chronic disease that affects millions of people worldwide.
The condition causes high blood sugar levels, which leads to serious health problems such as heart attacks, strokes, blindness, kidney failure, amputations, and even death. If left untreated, diabetes can cause life-threatening complications.
In 2017 alone, over 422 million adults had diabetes, according to the World Health Organization (WHO). This number is expected to rise to 642 million by 2045. The U.S. Food and Drug Administration (FDA) approved Mounjaro™ (tirzepatide) injection, Eli Lilly and Company’s (NYSE: LLY) new once-weekly GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
Tirzepatide is used in combination with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. It lowers blood sugar by releasing the body’s natural insulin and decreasing the amount of sugar the liver makes.
How Does Mounjaro Work For Weight Loss & Obesity Treatment?
Mounjaro has not been studied in patients with a history of pancreatitis and is not indicated for use in patients with type 1 diabetes mellitus.
As the first and only FDA-approved GIP and GLP-1 receptor agonist, Mounjaro is a single molecule that activates the body’s receptors for GIP and GLP-1, which are natural incretin hormones.
Wegovy Versus Mounjaro: What Is the Best Option For Obesity Treatment?
Wegovy and Mounjaro are two injectable prescription medications that help lower blood sugar and A1C levels and aid in weight loss.
However, these medications have different active ingredients and recommended dosages. The Food and Drug Administration (FDA) has also approved them to treat different conditions.
What are the active ingredients in Wegovy versus Mounjaro?
The active ingredient in Wegovy is semaglutide and the active ingredient in Mounjaro is tirzepatide. Their mechanisms of action will differ slightly.
Semaglutide mimics the glucose-like peptide (GLP)-1 hormones in the body.
Tirzepatide mimics both the GLP-1 and the glucose-dependent insulinotropic polypeptide (GIP) hormones in the body. GIP hormones aid GLP-1 hormones in their digestive and metabolic action, enhancing their ability to regulate appetite and prevent overeating.
Wegovy and Mounjaro are similar drugs, but they cannot be combined or used at the same time. Mounjaro delivered superior and consistent A1C reductions against all of the comparators throughout the SURPASS program, which was designed to assess Mounjaro’s efficacy and safety in a broad range of adults with type 2 diabetes who could be treated in clinical practice.
Wegovy is FDA-approved for the treatment of obesity and to aid in weight loss.
Mounjaro is FDA-approved as a treatment for managing blood sugar levels in people with type 2 diabetes. The average person who takes the maximum dose of Mounjaro (15 mg per week) has been reported to lower their A1C by 2.3%.
People struggling with insulin resistance and weight gain may be prescribed one of these medications. This is because, in addition to blood sugar management, they also slow digestion and suppress appetite.
Are There Any Side Effects Of Using Mounjaro?
Side effects reported in at least 5% of patients treated with Mounjaro include nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion (dyspepsia), and stomach (abdominal) pain. The labeling for Mounjaro contains a Boxed Warning regarding thyroid C-cell tumors.
“Lilly has a nearly 100-year heritage of advancing care for people with diabetes – never settling for current outcomes. We’re not satisfied knowing that half of the more than 30 million Americans living with type 2 diabetes are not reaching their target blood glucose levels,” said Mike Mason, president of Lilly Diabetes. “We are thrilled to introduce Mounjaro, which represents the first new class of type 2 diabetes medication introduced in almost a decade and embodies our mission to bring innovative new therapies to the diabetes community.”
Is Mounjaro A Safe Weight Loss Medication? – How to take
- Read the Instructions for Use that come with Mounjaro.
- Use Mounjaro precisely as your healthcare provider says.
- Mounjaro is injected under the skin (subcutaneously) of your stomach (abdomen), thigh, or upper arm.
- Use Mounjaro 1 time each week, at any time of the day.
- Do not mix insulin and Mounjaro in the same injection.
- If you take too much Mounjaro, call your healthcare provider or seek medical advice promptly.
Patients or healthcare professionals with questions about Mounjaro can visit www.Mounjaro.com or call The Lilly Answers Center at 1-800-LillyRx (1-800-545-5979).
Tirzepatide is also under regulatory review for treating type 2 diabetes in Europe, Japan, and several other markets.
Morbid Obesity: Transform your life one step at a time
Key Players in the Diabetes Market: Leading the Way in Diabetes Care
In the diabetes market, several key players are known for their contributions to diabetes treatment and management. These companies have developed innovative products and solutions to help individuals with diabetes lead healthier lives. Some of the notable players in the diabetes market include:
- Novo Nordisk: Novo Nordisk is a global pharmaceutical company specializing in diabetes care. It develops and manufactures a wide range of diabetes medications, including insulin products, oral antidiabetic drugs, and injectable therapies.
- Eli Lilly and Company: Eli Lilly is another major player in the diabetes market. It offers a variety of diabetes medications, including insulin products, GLP-1 receptor agonists, and oral antidiabetic drugs. It also provides resources and support for individuals living with diabetes.
- Sanofi: Sanofi is a multinational pharmaceutical company with a strong presence in the diabetes market. They produce insulin products, oral antidiabetic drugs, and combination therapies. Sanofi is committed to advancing diabetes care through research, innovation, and patient support.
- Johnson & Johnson is a diversified healthcare company that operates in various sectors, including diabetes care. It offers a range of diabetes products, including blood glucose monitoring systems, insulin pumps, and insulin delivery devices.
- Abbott Laboratories: Abbott Laboratories is a healthcare company that develops and manufactures various medical devices, diagnostics, and nutritional products. It is known for its diabetes care products, such as glucose monitoring systems, continuous glucose monitoring (CGM) systems, and diabetes management software.
These are just a few examples of the prominent players in the diabetes market. Each of these companies plays a significant role in advancing diabetes treatment and improving the lives of individuals with diabetes through its products, services, and commitment to research and development.
It’s important to note that this list is not exhaustive, as many other companies are also making significant contributions to the diabetes market.
Mounjaro and Wegovy for Weight Loss Reviews
I'm diabetic and overweight 225 pounds I'm on my third injection at 2.5.. first 2 days after the injection not as hungry then hungry come at full force I eat normal meals as always I've lost 3 pounds loads of energy that I love was on Trulicity for 2 years weight stayed the same. So I hope this is better.
Amy
Female 45-54
I was on it for 6 weeks. It was $1000 per month. I do not have diabetes so it was not covered. I had severe Nausea from Mounjaro and the Heartburn was awful. Vomiting was almost daily. I had zero appetite which caused the weight loss (7 1/2 lbs. in 2 weeks). My energy is returning, the nausea is abating, and I can eat again.
C
Female 65-74
40 yo female with PCOS, Diabetes type 2, I have been struggling for years and tried everything and it has been a yoyo effect. On September 08, 2022, I was 225.6 LBS and I had my first dose of Mounjaro 2.5 mg, now I am on week 5 and taking Mounjaro 5 mg now. Today is 10/16/22 I am 114.4 lbs
Michale
Female, 35-44
Regular check-ups and constant communication with your healthcare team are essential. Remember, managing diabetes is a team effort, and you’re never alone in this journey!
Wow, this sounds like a groundbreaking approach to obesity treatment! I’m really curious to learn more about Mounjuro and how it can help in the journey towards a healthier life
Thanks, Explains the importance of setting SMART goals in weight loss and how to do it effectively.
Managing morbid obesity typically involves a combination of lifestyle changes, such as improving diet and increasing physical activity, as well as potentially incorporating medical interventions, such as medications or in severe cases, surgery. It is important to work with healthcare professionals to create a personalized and sustainable plan for weight management to improve overall health and quality of life.
It’s important to remember that managing morbid obesity is a journey, not a destination. Celebrate every small victory and be patient with yourself.